Erytech confirms focus of eryaspase on solid tumors and ceases development in acute lymphoblastic leukemia

This article was originally published here

Erytech Pharma has announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply